Search Results - "NALDI, L."

Risk of infections in psoriasis. A lesson to learn during the SARS‐CoV‐2 pandemic by Naldi, L.

“…Linked Article: Yiu et al. Br J Dermatol 2021; 184:78–86…”
Get full text

The skin as a target for SARS‐CoV‐2 infection: exploiting the web for suitable data by Naldi, L.

“…Linked Article: Visconti et al. Br J Dermatol 2021; 184:880–887…”
Get full text

Biologic treatment for psoriasis and cancer: an increased risk for most cancers could not be ruled out by Naldi, L.

“…Linked Article: Peleva et al. Br J Dermatol 2018; 178:103–113…”
Get full text

Dermatologists and SARS‐CoV‐2: the impact of the pandemic on daily practice by Gisondi, P., Piaserico, S., Conti, A., Naldi, L.

“…Since the first case of ‘pneumonia of unknown aetiology’ was diagnosed at the Wuhan Jinyintan Hospital in China on 30 December 2019, what was recognized…”
Get full text

Finding a HOME for outcome measures in atopic dermatitis by Naldi, L.

“…Linked Article: Spuls et al. Br J Dermatol 2017; 176:979–984…”
Get full text

Conflicts of interest among academic dermatologists: freedom or constraint? by Naldi, L.

“…Summary Intangible and institutional conflicts of interest can particularly affect academia. Academic scientists have peculiar social responsibilities with…”
Get full text

Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update by Gisondi, P., PIaserico, S., Bordin, C., Alaibac, M., Girolomoni, G., Naldi, L.

“…On 11 March 2020, the World Health Organization (WHO) has declared the novel coronavirus disease (COVID‐19) a global pandemic, caused by the severe acute…”
Get full text

Lifestyle intervention should be an essential component of medical care for skin disease: a challenging task by Naldi, L.

“…ORIGINAL ARTICLE, p 1116…”
Get full text

Administrative data and scientific evidence: a lesson from France – the safety of systemic treatment for psoriasis during the COVID‐19 pandemic by Cazzaniga, S., Naldi, L.

“…Linked Article: Penso et al. Br J Dermatol 2022; 186:59–68…”
Get full text

The impact of the COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience by Gisondi, P., Facheris, P., Dapavo, P., Piaserico, S., Conti, A., Naldi, L., Cazzaniga, S., Malagoli, P., Costanzo, A.

Get full text

The global state of psoriasis disease epidemiology: a workshop report by Griffiths, C.E.M., Walt, J.M., Ashcroft, D.M., Flohr, C., Naldi, L., Nijsten, T., Augustin, M.

“…Summary The International Psoriasis Council, a global nonprofit organization dedicated to innovation across the full spectrum of psoriasis, led a symposium to…”
Get full text

Melanoma excision: how deep must we go? by Naldi, L.

“…ORIGINAL ARTICLE, p 1391…”
Get full text

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study by Kardaun, S.H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C.Y., Creamer, D., Sidoroff, A., Naldi, L., Mockenhaupt, M., Roujeau, J.C.

“…Summary Background Cases of severe drug hypersensitivity, demonstrating a variable spectrum of cutaneous and systemic involvement, are reported under various…”
Get full text

Diet and physical exercise in psoriasis: a randomized controlled trial by Naldi, L., Conti, A., Cazzaniga, S., Patrizi, A., Pazzaglia, M., Lanzoni, A., Veneziano, L., Pellacani, G.

“…Summary Background Increased body mass index and weight gain are risk factors for psoriasis, and the prevalence of obesity in patients with psoriasis is higher…”
Get full text

Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR) by Sidoroff, A., Dunant, A., Viboud, C., Halevy, S., Bavinck, J.N. Bouwes, Naldi, L., Mockenhaupt, M., Fagot, J-P., Roujeau, J-C.

“…Summary Background  Acute generalized exanthematous pustulosis (AGEP) is a disease characterized by the rapid occurrence of many sterile, nonfollicular…”
Get full text

Prevalence of contact allergy in the general population in different European regions by Diepgen, T.L., Ofenloch, R.F., Bruze, M., Bertuccio, P., Cazzaniga, S., Coenraads, P.-J., Elsner, P., Goncalo, M., Svensson, Å., Naldi, L.

“…Summary Background Population‐based studies about contact allergy are scarce. Objectives To obtain reliable estimates of the prevalence of contact allergy in…”
Get full text

Insights into Sars‐CoV‐2 vaccination in patients with chronic plaque psoriasis on systemic treatments by Gisondi, P., Geat, D., Naldi, L., Piaserico, S.

Get full text

Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus by Mrowietz, U., Barker, J., Boehncke, W.‐H., Iversen, L., Kirby, B., Naldi, L., Reich, K., Tanew, A., Kerkhof, P.C.M., Warren, R.B.

“…Fumaric acid esters (FAEs) are a group of small molecules that were first investigated for the treatment of psoriasis in 1959. The first fumarate‐based drug –…”
Get full text

Prevalence of skin disease in a population‐based sample of adults from five European countries by Svensson, A., Ofenloch, R.F., Bruze, M., Naldi, L., Cazzaniga, S., Elsner, P., Goncalo, M., Schuttelaar, M.‐L.A., Diepgen, T.L

“…Summary Background There is a lack of prevalence data on skin diseases in the general adult population; most studies have been carried out in small, national…”
Get full text

Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID‐19 vaccine by Sechi, A., Pierobon, E., Pezzolo, E., Germi, L., Trevisan, G., Zardo, D., Riva, G., Mondino, S., Naldi, L.

Get full text